A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Tadashi SakaneTakayuki MuraseKatsuhiro OkudaKosuke SaidaAyako MasakiTakeshi YamadaYushi SaitoRyoichi NakanishiHiroshi InagakiPublished in: Histopathology (2019)
Mutations in the EGFR pathway and TP53 in thymic carcinoma may be frequent, and the EGFR pathway mutations may be associated with a poor prognosis in thymic squamous cell carcinoma patients. The therapeutic significance of gene mutations in thymic carcinoma should be further clarified.
Keyphrases
- small cell lung cancer
- poor prognosis
- epidermal growth factor receptor
- tyrosine kinase
- squamous cell carcinoma
- end stage renal disease
- long non coding rna
- genome wide
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cell proliferation
- signaling pathway
- peritoneal dialysis
- prognostic factors
- copy number
- wild type
- gene expression
- radiation therapy
- patient reported outcomes
- dna methylation